- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
- Interventions
- Ibuprofen and acetaminophen, Ibuprofen and placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 5 Days to 21 Days
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pregnancy
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Female only
- Enrollment
- 1,919 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2012
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Royal Oak, Michigan
- Conditions
- Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 17
- States / cities
- San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
- Conditions
- Long QT Syndrome
- Interventions
- QTc Meter
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 5 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Myotonic Dystrophy 1, Excessive Daytime Sleepiness
- Interventions
- Pitolisant Oral Tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
- Conditions
- Atopic Dermatitis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Atopic Dermatitis, Secondary Infection
- Interventions
- Retapamulin 1%
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- CRD-TMH-001
- Drug
- Lead sponsor
- Cure Rare Disease, Inc
- Other
- Eligibility
- 18 Years to 28 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Fabry Disease
- Interventions
- 4D-310
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 4
- States / cities
- La Jolla, California • Atlanta, Georgia • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Wrinkle
- Interventions
- MCD
- Device
- Lead sponsor
- Cytrellis Biosystems, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Sacramento, California • Greenwood Village, Colorado • Miami, Florida + 3 more
- Conditions
- Glycogen Storage Disease, Pompe Disease
- Interventions
- alglucosidase alfa
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 2
- States / cities
- Cambridge, Massachusetts • Grand Rapids, Michigan
- Conditions
- Cellulite
- Interventions
- Sofwave
- Device
- Lead sponsor
- Sofwave Medical LTD
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 5
- States / cities
- Sacramento, California • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Mycobacterium Infections, Non-tuberculous
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
- Interventions
- Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
- Combination Product · Other
- Lead sponsor
- Kari Nadeau, MD, PhD
- Other
- Eligibility
- 1 Week to 12 Weeks
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
- Conditions
- Atopic Dermatitis, Type 1 Hypersensitivity
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
- Interventions
- Chewing device only, Myo Munchee and Oral Motor Therapy Treatment, Oral Motor Therapy Treatment Arm
- Device · Other
- Lead sponsor
- Myo Munchee (Operations) Pty Ltd
- Industry
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Lactose Intolerance
- Interventions
- Bifidobacterium adolescentis IVS-1 capsule, Placebo cellulose capsule
- Dietary Supplement · Other
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Phenylketonuria
- Interventions
- sapropterin dihydrochloride, Moxifloxacin, Moxifloxacin placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Fetal Alcohol Spectrum Disorder
- Interventions
- Dialectical Behavior Therapy for Adolescents
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 14 Years to 17 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Cascade Screening
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Inhaled Nitric Oxide, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 5 Days to 14 Days
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Twin to Twin Transfusion Syndrome
- Interventions
- Curved KARL STORZ fetoscope, Conventional Scopes
- Device
- Lead sponsor
- Jimmy Espinoza
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas